Global interventional therapies firm Penumbra is set to introduce Lantern microcatheter at the Society for Interventional Radiology 2016 meeting (SIR 2016) in Vancouver Convention Center, which will be held from 2 to 7 April.
Lantern is a low profile and high flow microcatheter developed to aid in the delivery of diagnostic agents such as contrast media and therapeutic devices such as occlusion coils to the peripheral vasculature.
Last December, the company secured 510(k) clearance from the US Food and Drug Administration (FDA) for Lantern. It is available in different lengths and tip shapes relevant to peripheral vascular procedures.
The distal segment of Lantern is visible under fluoroscopy to assist in the navigation and visualization of the microcatheter during procedures.
Penumbra chairman and CEO Adam Elsesser said: "Like many Penumbra products, the Lantern microcatheter is unique in its design and helps address physician needs for a low profile, high flow microcatheter.
"It is designed to track distally through the peripheral vasculature, yet can be used for high flow contrast injections, combining these desired properties into one microcatheter."
At the event, the firm will also present the results of the multicenter PRISM study, which evaluated the safety and efficacy of the Indigo system for peripheral and visceral arterial thrombi and emboli.
The company’s other embolization devices include Ruby coil, Penumbra occlusion device (POD) and POD packing coil.